JEB Technologies and Medovate, two medical device development and commercialisation companies based in the Eastern region, have signed a distribution agreement with Murray Medical Solutions Pty Ltd, granting them rights to distribute CamPROBE® (The Cambridge Prostate Biopsy Device) across Australia and New Zealand.
Professor Vincent Gnanapragasam, a leading urology expert, along with his team at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust developed the CamPROBE device intended to facilitate transperineal prostate biopsies under local anaesthetic.
Cambridge Enterprise collaborated with healthcare innovation consultancy Health Tech Enterprise to secure intellectual property protection for the CamPROBE device. They also assisted in obtaining a grant from the National Institute for Health and Care Research (NIHR), which facilitated the refinement, clinical evaluation and eventual commercialisation of the CamPROBE device.
The inventors of the CamPROBE collaborated with the product development and manufacturing company JEB Technologies to obtain CE marking for the device.
“This is genuine progress on CamPROBE®’s journey and another tremendous example of how an innovative clinical-academic like Vincent can turn an idea into a product that positively impacts patients’ lives.”
CamPROBE facilitates transperineal biopsy acquisition using simultaneous local anaesthetic delivery through an integrated needle. It is an alternative to transrectal and other transperineal devices, using only two body entry puncture points, resulting in low pain scores and improved patient comfort and patient acceptability. Procedural access through the perineum reduces complications due to infections and sepsis, compared to transrectal procedures.
Murray Medical Solutions is an Australian-owned specialised medical device company based in Sydney, Australia. Founded in 2015 Murray Medical Solutions specialises in supplying high-quality medical and surgical products and equipment to the Health and Medical sector and is known for its personalised service, clinical expertise and commitment to quality.
With a notable global increase in the demand for prostate cancer biopsies and diagnostics driven by ageing populations, heightened awareness and extended screening programs-CamPROBE has the potential to significantly enhance the patient and healthcare experience.
CamPROBE device
Stuart Thomson, Vice President of Business Development, Medovate and JEB Technologies Limited, said:
“I’m thrilled to announce our new partnership with Murray Medical Solutions, a company that shares our commitment to delivering innovative, high-quality medical devices to healthcare professionals. With their strong track record and specialisation in innovative medical device solutions, Murray Medical is an ideal distribution partner for our technology. Through this new partnership, the CamPROBE® system (developed in collaboration with NHS clinical innovators) will become accessible to urologists, across Australia and New Zealand, supporting broader use in clinical settings. We very much look forward to working with the Murray Medical team and we are excited to begin this journey with them.”
Stuart Keighran, Director, Murray Medical Solutions, commented:
“Murray Medical is delighted to have partnered with JEB Technologies and Medovate to become the exclusive distributor across Australia and New Zealand for the CamPROBE device. We have always paid great attention to doctors and urologists’ needs and feedback and that is why we are honoured to provide them with this revolutionary technology for performing a prostate biopsy.
Murray Medical has a long tradition in supplying parts of Australasia with innovative solutions in urology and other therapy-area products that create benefits for clinicians and their patients. The addition of the CamPROBE® system aligns perfectly with this tradition and allows us to keep improving patients’ quality of life. This agreement will allow urologists across Australia and New Zealand to offer their patients access to this technology, helping enhance patient care in the field of transperineal prostate biopsy.”
Dr Terry Parlett, Commercialisation Director, Deputy Head of Life Sciences, Cambridge Enterprise, shared:
“It is truly exciting to see CamPROBE® become available to patients in the Australasian market through this partnership. This is genuine progress on CamPROBE®’s journey and another tremendous example of how an innovative clinical-academic like Vincent can turn an idea into a product that positively impacts patients’ lives. Such journeys are a team game and CamPROBE® is a great example of how a passionate innovator, the NHS and academic ecosystem can work together with industry to deliver their innovations into the healthcare system.”
